Skip to content

Rigel Pharmaceuticals RIGL Single reportable segment — Revenue recognized

Similar metrics at other companies

Shattuck Labs, Inc. logo
STTKReportable Segment — Revenue
$0
Arbutus Biopharma Corporation logo
ABUSReportable Segment — Revenue
$179.13M+10,055%
Archer Aviation logo
ACHRReportable Segment — Revenue
$1.6M
Roivant Sciences logo
ROIVReportable Segment — Revenue
$2.52M-66.7%
BridgeBio Pharma logo
BBIOReportable Segment — Revenue
$194.52M+66.8%
Elanco Animal Health Inc. logo
ELANReportable Segment — Revenue
$1.37B+14.9%

Other financials

Income statement

See full
Revenue$58.8M+10.3%
Gross profit$54.2M+10.8%
Operating income$11.9M-7.0%
Net income$8.7M-24.4%
EPS (diluted)$0.44-30.2%

Balance sheet

See full
Cash & equivalents$24.5M-46.6%
Total debt$68.4M+5,079%
Total equity$399.9M+2,054%
Total assets$504.6M+187%

Cash flow

See full
Operating cash flow$2.7M+405%
CapEx$73.0K
Free cash flow-$22.0M

Valuation

See full
Market cap$684.39M+102%
Enterprise value$728.29M+148%
P/E1.9×-7.2×
P/S2.3×+0.6×

Profitability

See full
Gross margin93.4%+3.7pp
Operating margin41.6%+19.9pp
Net margin121.5%+103pp
FCF margin-61.7%

Returns & leverage

See full
Return on equity174.1%
Debt / equity0.2×+0.1×
Current ratio2.6×+0.4×

Where this comes from

Reported directly by Rigel Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rigel Pharmaceuticals's single reportable segment — revenue recognized.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Rigel Pharmaceuticals's single reportable segment — revenue recognized?
Rigel Pharmaceuticals (RIGL) reported single reportable segment — revenue recognized of $58.82M in Q1 2026.
What does single reportable segment — revenue recognized mean?
Represents the total revenue generated by the company's primary operating segment from contracts with customers. This includes product sales, licensing fees, and milestone payments, reflecting the core commercial success of the firm's drug portfolio.